The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global biobanking market reached a value of US$ XX Billion in 2021. Looking forward, IMARC Group expects the market to grow at a CAGR of XX% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Biobanking refers to the process of analyzing and storing information of human biospecimens, which are collected from healthy volunteers or people with a particular condition. This information is used in research and academic studies to improve the understanding of health and different diseases. Presently, modern biobanks have large-scale analysis of specific disease biomarkers, which include biological or digital material with well-annotated clinical and biological data. They provide a basis for improving personalized medical approaches wherein effective biomarker identification is crucial for disease diagnosis and prognosis.
Biobanking nowadays is gaining widespread adoption in collecting high-quality and well-annotated human biospecimens, understanding the pathogenic mechanisms, and identifying therapeutic targets of coronavirus disease (COVID-19). Apart from this, due to the increasing prevalence of new infectious and chronic diseases, there is a rise in the demand for biobanking to develop diagnostics that can accurately and quickly identify pathogens. This can also be accredited to the growing aging population, in confluence with the escalating demand for regenerative medicine and personalized treatment across the globe. Moreover, developments in genomics, metagenomics, proteomics, disease biology, bioenergy, environmental remediation, and allied fields are contributing to the market growth. Besides this, health agencies of numerous countries are investing in virtual biobank network models that offer a faster and sustainable solution. These network models offer electronic databases that help investigators to locate biospecimens and data mining from multiple biobanks. Furthermore, leading market players are offering a diverse portfolio of biobanking products and services that enable sharing of insights and critical information to advancing science. These innovations are projected to strengthen the growth of the market in the coming years.
IMARC Group provides an analysis of the key trends in each sub-segment of the global biobanking market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on specimen type, biobank type, application and end user.
Breakup by Specimen Type:
Breakup by Biobank Type:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Brooks Automation Inc., Bay Biosciences LLC, Boca Biolistics, Ctibiotech, Cureline Inc., Firalis, Greiner Bio-One International GmbH, Hamilton Company, Merck KGaA, ProteoGenex Inc., Thermo Fisher Scientific Inc. and VWR Corporation (Avantor Inc.).
|Base Year of the Analysis||2021|
|Segment Coverage||Specimen Type, Biobank Type, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Brooks Automation Inc., Bay Biosciences LLC, Boca Biolistics, Ctibiotech, Cureline Inc., Firalis, Greiner Bio-One International GmbH, Hamilton Company, Merck KGaA, ProteoGenex Inc., Thermo Fisher Scientific Inc. and VWR Corporation (Avantor Inc.).|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at